ImClone Systems Inc (formerly IMCL)

[upwestside]

jb,


i asked you before but i dont think you replied.

i asked what if the data was not as robust as avastins. how would erb penetrate 1st line then? just trying to get some clarity. already schmidt is quoted as saying erb penetration into 1st line is no threat to avas. i guess im trying to find out if erb can *replace* avas as the drug of choice in 1st line and the implications if the data is not as strong as expected. i think u mentioned avas has no 1st line trials and got 1st line use by default (something like that - i dont remember). could u please comment, thanks.